SPYRE THERAPEUTICS INC (SYRE)
NASDAQ • Healthcare
Last close at August 11, 2026 at 20:00 UTC
Fundamentals Charts
About SPYRE THERAPEUTICS INC
Spyre Therapeutics, Inc. is a preclinical Biotechnology company listed on the NASDAQ Capital Market as SYRE that develops treatments for inflammatory bowel disease. The company focuses on drug candidates for people with ulcerative colitis and Crohn's disease, placing it in the biotech side of the healthcare sector.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
SPYRE THERAPEUTICS INC's Technical Indicators Summary
SYRE, at about 104.64, displays constructive price structure across timeframes that supports a Buy assessment. The stock trades well above short-, medium- and long-term moving averages, momentum measures are positive with a bullish MACD reading and rising short-term momentum, and the classic pivot is slightly below the market. Trend strength is modest, as ADX is low, while volatility is elevated with a higher ATR and on-balance volume is soft, which tempers the signal. Overall the technical profile is favorable but not without higher volatility and weaker volume. Technical takeaway: Buy — multi‑timeframe moving‑average support with elevated volatility.
| Indicator | Value |
|---|---|
RSI (14) | 57.93 |
Stochastic %K (14, 3, 3) | 75.25 |
CCI (20) | 83.43 |
WPR (14) | -22.19 |
Momentum (10) | 6.77 |
MFI | 56.27 |
MACD Level (12, 26) | 3.26 |
Bollinger Bands | $94.30 - $107.56 |
ATR (14) | $5.73 (5.48%) |
ADX (14) | 17.90 |
OBV | 45,204,748 |
Classic Pivot Point | $102.67 |
Fibonacci Pivot Point | $102.67 |
Exponential Moving Averages | $59.40 - $102.85(5 indicators) |
Simple Moving Averages | $55.61 - $102.51(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
SYRE is up 1.49% from yesterday’s close of 102.74. Subdued interest shows up in volume at just 0.42× the typical level. SYRE's TL1A/IL-17A/F trial in hidradenitis suppurativa is described as a potential game changer, boosting longer-term outlook.
Trading Volume
Below 10d avg (728.5K)
309.5K
vs S&P 500 Today
Outperforming Market
+1.24%
52-Week Position
Near highs
95.9%
Updated: August 12, 2026 at 16:42 UTC